Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk

Citation:

Kensler KH, Liu EZF, Wetstein SC, Onken AM, Luffman CI, Baker GM, Collins LC, Schnitt SJ, Bret-Mounet VC, Veta M, et al. Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29 (11) :2358–2368.

Last updated on 11/05/2020

Latest News

NUS ncRNA Symposium and Liquid Biopsy Summit 2022

September 26, 2022

Dr. Heng was one of the invited international speakers at the National University of Singapore non-codingRNA symposium 2022.

The title of her talk was, "Plasma miRNAs associated with cisplatin sensitivity in breast cancer."

https://medicine.nus.edu.sg/core-facilities/noncoding-rna-ncrna/events-workshops-trainings/ncrnalbx2022/

Applications of Medical AI Workshop, MICCAI

July 25, 2022

Dr Baker's abstract, "Effect of testosterone therapy on quantitative breast lobular atrophy in transmasculine individuals" has been accepted for a Poster presentation at the Applications of Medical AI Workshop at Medical Image Computing and Computer Assisted Intervention (MICCAI) Meeting, Singapore.

Congratulations to the team!

College of American Pathologist (CAP) Meeting 2022

May 27, 2022

Congratulations to Dr Baker. Her abstract, "Comparing the Immunohistochemistry Scoring of Breast Tumor Tissue Microarrays Using Definiens, InForm, and QuPath" has been accepted for Poster presentation at the CAP annual meeting 2022.

NCI Health Disparity Workshop

May 6, 2022

Dr. Heng will be speaking at a health disparity workshop organized by the NCI Center for Cancer Research and the Division of Cancer Epidemiology & Genetics.

She will present her group's multidisciplinary research on transgender breast cancer risk and treatment outcomes.

Precision RNA Medicine Core Detection Workshop

April 29, 2022

Dr. Heng was one of the speakers at the BIDMC Precision RNA Medicine Core Detection Workshop, "Tools for the discovery and validation of clinically important microRNA biomarkers” on Friday, April 29^th at 9:00 AM – 10:30 AM ET.

The title of her talk was, "“Plasma miRNAs associated with cisplatin sensitivity in breast cancer.”

Applications of Medical AI (AMAI) at MICCAI 2022

April 21, 2022

Dr. Heng joins the Program Commitee of the first workshop on Applications of Medical AI (AMAI), taking place as a Satellite Event of MICCAI 2022 on Sep 18 2022 in Singapore.

https://sites.google.com/view/amai2022/home#h.nbe1l6goxbom

Jan Heng, Ph.D.

290px-harvard_wreath_logo_2.png